Wall Street brokerages expect that Teleflex Incorporated (NYSE:TFX) will post $601.67 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Teleflex’s earnings. The highest sales estimate is $605.30 million and the lowest is $598.50 million. Teleflex posted sales of $513.93 million during the same quarter last year, which would suggest a positive year over year growth rate of 17.1%. The firm is expected to issue its next earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that Teleflex will report full year sales of $601.67 million for the current year, with estimates ranging from $2.15 billion to $2.16 billion. For the next fiscal year, analysts forecast that the business will post sales of $2.43 billion per share, with estimates ranging from $2.41 billion to $2.46 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Teleflex.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. The company had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS.

TFX has been the topic of a number of research reports. Needham & Company LLC upped their target price on Teleflex from $228.00 to $237.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. KeyCorp restated a “hold” rating on shares of Teleflex in a report on Wednesday, September 6th. Morgan Stanley upgraded Teleflex from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $220.00 to $274.00 in a report on Wednesday, September 6th. Leerink Swann upgraded Teleflex from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $227.00 to $266.00 in a report on Thursday, September 7th. Finally, Jefferies Group increased their price objective on Teleflex from $253.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $274.44.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $265.32, for a total value of $53,064.00. Following the transaction, the director now owns 8,080 shares in the company, valued at $2,143,785.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Benson Smith sold 2,000 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $258.10, for a total value of $516,200.00. Following the transaction, the chief executive officer now owns 76,634 shares in the company, valued at approximately $19,779,235.40. The disclosure for this sale can be found here. Insiders sold 2,400 shares of company stock worth $616,700 in the last 90 days. 2.39% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Toronto Dominion Bank grew its holdings in Teleflex by 14.5% during the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 70 shares during the last quarter. Advisory Services Network LLC grew its holdings in Teleflex by 933.8% during the second quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after purchasing an additional 747 shares during the last quarter. Cornerstone Capital Management Holdings LLC. bought a new stake in shares of Teleflex in the second quarter valued at approximately $175,000. Calamos Advisors LLC bought a new stake in shares of Teleflex in the second quarter valued at approximately $206,000. Finally, Archford Capital Strategies LLC boosted its position in shares of Teleflex by 29,025.0% in the second quarter. Archford Capital Strategies LLC now owns 1,165 shares of the medical technology company’s stock valued at $217,000 after acquiring an additional 1,161 shares during the period. Institutional investors own 88.97% of the company’s stock.

Shares of Teleflex (NYSE TFX) traded down $2.69 on Monday, hitting $248.82. The stock had a trading volume of 176,500 shares, compared to its average volume of 262,788. The firm has a market cap of $11,209.16, a P/E ratio of 45.41, a price-to-earnings-growth ratio of 2.13 and a beta of 1.09. Teleflex has a one year low of $157.80 and a one year high of $271.23. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Wednesday, November 15th were issued a $0.34 dividend. The ex-dividend date was Tuesday, November 14th. This represents a $1.36 dividend on an annualized basis and a yield of 0.55%. Teleflex’s dividend payout ratio is currently 24.82%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/zacks-brokerages-expect-teleflex-incorporated-tfx-will-post-quarterly-sales-of-601-67-million/1790867.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with Analyst Ratings Network's FREE daily email newsletter.